BROCHURE
Jens Hahne is a UK,Institute of Cancer Research,UK

Jens Hahne

UK

Organizing Committee

UK

Institute of Cancer Research

BIOGRAPHY

Jens   received   his   PhD   in   biochemistry   from   the   Albert-Ludwigs-University   Freiburg   i.Br. (Germany). During several postdoc positions [Department of Molecular Pathology at the University of Bonn (Germany), Charite Berlin (Germany), Department of Gynaecology and Obstetrics at the University of Wuerzburg (Germany)] he received a broad training and knowledge in molecular pathology and cancer research. At the moment he is working in the Department of Molecular Pathology at the ICR (London, UK).

PUBLICATIONS

Hahne, J. C., Herchenröder, O., Meyer, W. K.-H., Thiesen, H.-J. and Schneider, J. (1999). Repression of the human immunodeficiency virus type 1 promoter by the human KRAB domain results in inhibition of virus production.

Okuducu, A. F., Janzen, V., Hahne, J. C., Ko, Y. and Wernert, N. (2003). Influence ofhistochemical stains on quantitative gene expression analysis after laser-assisted microdissection.

Hahne, J. C., Rothhammer, T., Florin, A., Poser, I., Soncin, F., Wernert, N. and Bosserhoff, A.-K. (2004). Characterisation of ets-1 expression in malignant melanoma. 

Okuducu, A. F., Hahne, J.C., von Deimling, A. and Wernert, N. (2005). Laser-assisted microdissection, techniques and application in pathology: an update. 

Sahin, A., Velten, M., Pietsch, T., Knuefermann, P., Okuducu, A. F., Hahne, J. C. and Wernert, N. (2005). Interaction of Ets-1 transcription factor by a specific decoy strategy reduces rat C6 glioma cell proliferation and mmp-9 expression. 

Kiriakidis, S., Högemeier, O., Starcke, S., Dombrowski, F., Hahne, J. C., Pepper, M., Jha, H. C. and Wernert, N. (2005). Novel tempeh (fermented soybean) isoflavones inhibit in-vivo angiogenesis in the chicken chorioallantoic membrane (CAM) assay.

Hahne, J. C., Okuducu, A. F., Kaminski, A., Florin, A., Soncin F. and Wernert, N. (2005). Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth. 

Okuducu, A. F., Janzen, V., Ko, Y., Hahne, J. C., Lu, H., Ma, Z. L., Albers, P., Sahin, A., Wellmann, A., Scheinert, P. and Wernert, N. (2005). Cellular retinoic acid-binding protein 2 (CRABP2) is down-regulated in prostate cancer. 

Jäger, R., Hahne J., Jacob A., Egert A., Schenkel J., Wernert N., Schorle H. and Wellmann A. (2005). Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas. 

Hahne, J. C., Fuchs, T., Haddouti, M., Bories, J. C. and Wernert, N. (2006). Expression pattern of matrix metalloproteinase and TIMP genes in fibroblasts derived from ets-1 knock out mice compared to wildtype mouse fibroblasts. 

Friedrichs, N., Hahne, J. C., Pepper, M. S., Rommerscheidt-Fuss, U., Büttner, R., Stelzner, F. and Wernert, N. (2006). Immunhistochemical quantification of lymph vessels, VEGF-C and VEGF receptors 2 and 3 in human sarcomas. 

Hahne, J.C., Kaminski, A., Haddouti, M., Florin, A., Wellmann, A. and Wernert, N. (2006). Tumour-stroma interactions between metastatic prostate cancer cells and fibroblasts. 

Naib-Majoni, W., Breipohl, W., El Shazli, E., Theuerkauf, I., Pleyer, U., Hahne, J. C. and Wernert, N. (2007). The Ets-1 transcription factor is involved in pterygial angiogenesis. 

Sterz, J., von Metzler, I., Hahne, J. C., Lamottke, B., Rademacher, J., Heider, U., Terpos, E. and Sezer, O. (2008). The potential of proteasome inhibitors in cancer therapy. Expert Opin. 

Haas, S., Park, T. W., Hahne, J. C. and Fischer, H. P. (2008). Influence of stromalreaction on uPA/PAI-1 expression in breast cancer tissue.

Hahne, J. C., Okuducu, A. F., Sahin, A., Faveur, V., Kiriakidis, S. and Wernert, N. (2008). The transcription factor Ets-1: its role in tumour development and strategies for its inhibition. 

Sahin, A., Vercamer, C., Kaminski, A., Fuchs T., Florin A., Hahne, J. C., Mattot, V., Pourtier-Manzanedo A., Pietsch, T., Faveur V. and Wernert, N.

Dominant-negative inhibition of Ets suppress tumor growth, invasion and migration inrat C6 glioma cells and reveals differentially expressed Ets target genes. 

Hahne, J. C., Kummer, S., Heukamp, L. C., Fuchs, T., Gun, M., Langer, B., von Ruecker, A. and Wernert, N. (2009). Regulation of protein tyrosine kinases in tumour cells by the transcription factor Ets-1.

Wellmann, A., Fogt, F., Hollerbach S., Hahne, J., Koenig-Hoffmann, K., Smeets, D. and Brinkmann U. (2009). Polymorphisms of the apoptosis-associated gene DP1L1 (deleted in polyposis 1-like 1) in colon cancer and inflammatory bowel disease.

Hahne, J. C., Okuducu, A. F., Fuchs, T., Florin, A. and Wernert, N. (2009). Identification of novel Ets-1 target genes in human fibroblasts. 

Hahne, J.C., Fuchs, T., Florin, A., Edwards, D., Pourtier, A., Soncin, F. and Wernert, N. (2011). Evaluation of effects caused by different spliced Ets-1 transcripts in fibroblasts. 

Engel, J. B., Martens, T., Hahne, J. C., Häusler, S., Krockenberger, M., Segerer, S. E., Djakovic, A., Meyer, S., Dietl, J., Wischhusen, J. and Hönig, A. (2012). Effects of Lobaplatin as single agent and in combination with TRAIL on the growth of triple negative p53 mutated breast cancers in vitro.

Hönig, A., Hahne, J. C., Meyer S., P. Kranke, Häusler, S., Diessner, J., Dietl, J. and Engel, J. B. (2012). PI3K-Inhibitor D-116883 is effective in in vitro models of ovarian cancer. 

Engel, J. B., Hahne, J. C., Häusler, S. F. M., Meyer, S., Segerer, S. E., Diessner, J., Dietl, J. and Hönig, A. (2012). Peptidomimetic GnRH antagonist AEZS-115 inhibits the growth of ovarian and endometrial cancer cells.

Hahne, J. C., Hönig, A., Meyer, S. R., Gambaryan, S., Walter, U., Wischhusen, J., Häussler, S. F. M., Segerer, S. E., Fujita, N., Dietl, J. and Engel, J. B. (2012). Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro

Hahne, J.C., Schmidt, H., Meyer, S.R., Engel, J.B., Dietl, J. and Hönig, A. (2013). Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple negative breast cancer. 

Hahne, J. C., Meyer, S. R., Gambaryan, S., Walter, U., Dietl, J., Engel, J. B. and Hönig,  A. (2013). Immune escape of AKT overexpressing ovarian cancer cells. 

Hahne, J. C., Meyer, S. R., Dietl, J., Polat B. and Hönig, A. (2013). Studies about the role of osteopontin-1 in endometrial cancer cells. 

Engel, J. B., Hönig, A., Kapp, M., Hahne, J. C., Meyer, S. R., Dietl, J. and Segerer, S. E. (2014). Mechanisms of tumor immune escape in triple-negative breast cancer (TNBC) with abd without mutated BRCA 1. A

Hahne, J.C., Meyer, S.R., Dietl, J. and Hönig, A. (2014). Effect of Cordyceps extract and a mixture of Ganoderma lucidum/Agaricus Blazi Murill extract on human endometrial  cancer cell lines in-vitro

Hahne, J. C., Kurz, A., Meyer, S. R., Engel, J. B., Dietl, J. and Hönig, A. (2015). Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer. 

Sclafani F., Chau I., Cunningham D., Peckitt C., Lampis A., Hahne J. C., Braconi C., Tabernero J., Glimelius B., Cervantes A., Begum R., Gonzalez de Castro D., Hulkki Wilson S., Eltahir Z., Wotherspoon A., Tait D., Brown G., Oates J. and Valeri N. (2015).

Hahne, J. C. (2015). Platinum-resistance and AKT over-expression in ovarian cancer. 

Smyth E. C., Fassan M., Cunningham D., Lampis A., Hahne J. C., Rugge M., Peckitt C., Nankivell M., Langley R., Ghidini M., Braconi C., Wotherspoon A., Grabsch H. I. and Valeri N. (2016). Effect of pathological tumour response and nodal status on survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. 

Eid R., Jakee J.E., Rashidy A., Asfour H., Omara S., Kandil M.M., Mahmood Z., Hahne J. and Seida A.A. (2016). Potential antimicrobial activities of probiotic lactobacillus strains isolated from raw milk.

Sclafani F., Chau I., Cunningham D., Lampis A., Hahne J. C., Ghidini M., Lote H., Zito D., Tabernero J., Glimelius B., Cervantes A., Begum R., Gonzalez de Castro D., Hulkki Wilson S., Peckitt C., Eltahir Z., Wotherspoon A., Tait D., Brown G., Oates J., Braconi C. and Valeri N. (2016). Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. 

Ghidini M., Hahne J.C., Trevisani F., Panni S., Ratti M., Toppo L. and Tomasello G. (2016). New developments in the treatment of chemotherapy induced neutropenia – focus on Balugrastim. 

El-Jakee J., Khelfa D.G., El-Safty M.M., Hahne J., Seida A., Marouf S.A. and Nagy S.S. (2016). Detection of Salmonella Typhimurium and Salmonella Enteritidis in Specific-Pathogen-Free and Commercial Eggs.

Trevisani F., Ghidini M., Larcher A., Lampis A., Manunta P., Sciarrone Alibrandi M.T., Zagato L., Citterio L., Dell’Antonio G., Carenzi C., Capasso G., Rugge M., Rigotti P., Bertini R., Cascione L., Briganti A., Salonia A., Benigni F., Braconi C., Fassan M., Hahne J.C., Montorsi F. and Valeri N. (2016). MicroRNAs as predictive biomarkers of chronic kidney disease in patients undergoing radical nephrectomy for clear cell renal cancer. 

Carotenuto P., Fassan M., Lampis A., Vicentini C., Cascione L., Paulus-Hock V., Boulter L., Guest R., Quagliata L., Hahne J.C., Ridgway R., Jamieson T., Athineos D., Veronese A., Visone R., Murgia C., Ferrari G., Evans T.R., MacLeod M., Feng G.I., Dale T., Negrini M., Forbes S., Terracciano L., Scarpa A., Patel T., Valeri N., Workman P., Sansom O. and Braconi C. (2017). Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. 

Lote H., Spiteri I., Ermini L., Roy A., McDonald A., Marka N., Balsitis M., Bose N., Simbolo M., Mafficini A., Lampis A., Hahne J. C., Trevisani F., Eltahir Z., Findlay C., Kalkman E. A. J., Werner B., Aktipis A., Maley C., Greaves M., Braconi C., White J., Fassan M., Scarpa A., Sottoriva A. and Valeri N. (2017). Carbon dating cancer: the chronology of a colorectal cancer patient with synchronous metastasis.

Ghidini M., Cascione L., Carotenuto P., Lampis A., Trevisani F., Previdi M. C., HahneJ.C., Huntingford I., Raj M., Passalacqua R., Zerbi A., Mescoli C., Cillo U., Rugge M., Roncalli M., Torzilli G., Rimassa L., Santoro A., Valeri N., Fassan M. and Braconi C. (2017). Characterization of the immune-related transcriptome in resected billary tract cancer. 

Khan K.H., Rata M., Cunningham D., Koh D.-M., Tunariu N., Hahne J.C., Vlachogian-nis G., Heyadat S., Marchetti S., Lampis A., Darvish Damavendi M., Lote H., Rana I., Williams A., Eccles S.A., Fontana E., Collins D.J., Elathir Z., Rao S., Watkins D.J., Starling N., Thomas J., Kalaitzaki E., Fotiadis N., Begum R., Bali M., Rugge M., Temple E., Fassan M., Chau I., Braconi C. and Valeri N. (2017). Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. 

 Hahne J. C., Engel J. B., Honig A., Meyer S. R., Zito D., Lampis A. and Valeri, N. (2017). The PI3K/AKT/mTOR-signal transduction pathway as drug target in triple-negative breast cancer. 

Ghidini M., Petrelli F., Hahne J.C., De Giorgi A., Toppo L., Pizzo C., Ratti M., Barni S. Passalacqua R. and Tomasello G. (2017). Clinical and molecular characterization of brain metastases from esophageal and gastritic cancer: a systematic review. 

Ghidini M., Fausto P., Ghidini A., Tomasello G., Hahne J.C., Passalacqua R. and Barni S. (2017). Clinical development of mTor inhibitors for renal cancer. 

Tomasello G.,  Valeri N.,  Ghidini M.,  Smyth E.C.,  Liguigli W.,  Toppo L.,  Mattioli R., Curti A., Hahne J.C., Negri F., Panni S., Ratti M., Lazzarelli S., Gerevini F., Colombi C., Panni A., Rovatti M., Treccani L., Martinotti M. and Passalacqua R. (2017). First-line dose-dense chemotherapy with Docetaxel, Cisplatin, Folinic Acid and 5-Fluorouracil (DCF) plus Panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction final results and biomarker analysis from an Italian Oncology Group for Clinical Research (GOIRC) phase II study. 

Lampis A., Carotenuto P., Vlachogiannis G., Cascione L., Hedayat S., Burke R., Clarke P., Bosma E., Simbolo M., Scarpa A., Yu S., Cole R., Smyth E., Fernández-Mateos J., Begum R., Hezelova B., Eltahir Z., Wotherspoon A., Fotidis N., Bali V.C., Nepal C., Stubbs M., Hahne J.C., Gasparini P., Guzzardo V., Croce C.M., Eccles S., Fassan M., Cunningham D., Andersen J.B., Workman P., Valeri N. and Braconi C. (2017). MiR-21 drives resistance to heat shock protein 90 inhibition in cholangiocarcinoma.

Vlachogiannis  G.,  Hedayat S.,  Vatsiou  A.,  Jamin  Y.,  Fernández-Mateos J.,  Khan K.,Lampis A., Eason K., Huntingford I., Burke R., Rata M., Koh D-M., Tunariu N., Collins D., Hulkki-Wilkinson S., Ragulan C., Spiteri I., Moorcraft S.Y., Chau I., Rao S., Watkins D., Fotiadis N., Darvish-Damavandi M., Lote H., Eltahir Z., Smyth E.C., Begum R., Clarke P., Hahne J.C., Dowsett M., de Bono J., Workman P., Sadanandam A., Fassan M., Sansom O.J., Eccles S., Starling N., Braconi C., Sottoriva A., Robinson S., Cunningham D. and Valeri N. (2018). Patient derived organoids based co-clinical trials in metastatic gastrointestinal cancers. 

Hahne J.C. and Valeri N. (2018). Non-coding RNAs and resistance to anticancer drugs in gastrointestinal tumours.

Khan K., Cunningham D., Werner B., Vlachogiannis G., Spiteri I., Heide T., Fernandez-Mateo J., Vatsiou A., Lampis A., Darvish Damavandi M., Lote H., Huntingford I.S., Hedayat S., Chau I., Tunariu N., Mentrasti G., Trevisani F., Rao S., Anandappa G., Watkins D., Starling N., Thomas J., Peckitt C., Khan N., Rugge M., Begum R., Hezelova B., Bryant A., Jones T., Prosezek P., Fassan M., Hahne J.C., Hubank M., Braconi C., Sottoriva A. and Valeri N. (2018). Longitudinal liquid biopsy and mathematical modelling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial. 

Ratti M., Lampis A., Hahne J.C., Passalacqua R. and Valeri N. (2018). Microsattelite instability in gastric cancer: molecular bases, clinical perspectives and new treatment approaches. 

Ghidini M., Hahne J.C., Frizziero M., Tomasello G., Trevisani F., Lampis A., Passalacqua R. and Valeri N. (2018). MicroRNAs as mediators of resistance mechanisms to small-molecule tyrosine kinase inhibitors in solid tumours. 

Sclafani F., Chau I., Cunningham D., Hahne J.C., Vlachogiannis G., Eltahir Z., Lampis A., Braconi C., Kalaitzaki R., Gonzalez de Castro D., Wotherspoon A., Capdevilla J., Glimelius B., Cervantes A., Begum R., Lote H., Hulkki Wilson S., Mentrasi G., Brown G., Tait D., Oates J. and Valeri N. (2018). KRAS and BRAF mutations in circulating tumour DNA from locally-advanced rectal cancer. 

Mensah, A.A., Cascione L., Gaudio E., Tarantelli C., Bomben R., Bernasconi E., Zito D., Lampis A., Hahne J.C., Rinaldi A., Stathis A., Zucca E., Kwee I., Gattei V., Valeri N., Riveiro M.E. and Bertoni F, (2018). Bromodomain and extra-terminal domain inhibition modulates microRNA expression in diffuse large B-cell lymphoma.

Ghidini M., Pizzo C., Botticelli A., Hahne J.C., Passalacqua R., Tomasello G. and Petrelli F. (2018). Biliary tract cancer: current challenges and future prospects. 

Smyth E.C., Nyamundanda G., Cunningham D., Fontana E., Ragulan C., Tan I.B., Lin S.J., Wotherspoon A., Nankivell M., Fassan M., Lampis A., Hahne J.C., Davies A.R., Lagergren J., Gossage J.A., Maisey N., Green M., Zylstra J.L., Allum W.H., Langley R.E., Tan P., Valeri N. and Sadanandam A. (2018). A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial. 

Anandappa G, Lampis A, Cunningham D, Khan KH, Kouvelakis K, Vlachogiannis G, Hedayat S, Tunariu N, Rao S, Watkins D, Starling N, Braconi C, Darvish Damavandi M, Lote H, Thomas J, Peckitt C, Kalaitzaki E, Khan N, Fotiadis N, Rugge M, Begum R, Rana I, Bryant A, Hahne JC, Chau I, Fassan M. and Valeri N. (2019). MicroRNA 31-3p expression and benefit from anti-EGFR inhibitors in metastatic colorectal cancer patients enrolled in the prospective phase II PROSPECT-C trial.

Ratti M., Hahne J.C., Toppo L., Castelli E., Petrelli F., Barni S., Tomasello G. and Ghidini M, (2019). Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data. 

Petrelli F., Ghidini M., Ghidini A., Perego G., Cabiddu M., Khakoo S., Oggionni E., Abeni C., Hahne J.C., Tomasello G. and Zaniboni A. (2019). Use of Antibiotics and Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies. 

Contributions to books:

Wernert, N., Kaminski, A., Haddouti, M. and Hahne, J. C. (2007). Tumor-Stroma Interactions of Metastatic Prostate Cancer Cell Lines – Analysis Using Microarrays. In: Methods in Molecular Biology, vol. 382, pp 223-238: Microarrays: Application and Data Analysis, Second Edition. Edited by J. B. Rampal, Humana Press Inc., 

Hahne, J. C., Honig, A., Engel J. B., Lampis, A. and Valeri, N. (2016). Analysing molecular mechanism related to therapy-resistance in in-vitro models of ovarian cancer. In: Gynecologic Cancers - Basic Sciences, Clinical and Therapeutic Perspectives. Edited by Samir A. Farghaly, InTech Open Scinces, Rijeka, Croatia.

Hahne J. C., Mirchev M., Kotzev I., Lampis A. and Valeri N. (2017). Biomarkers for monitoring response to therapies and detection of acquired resistance in advanced gastrointestinal cancers. In: Frontiers in Clinical Drug Research – Anti-cancer agents, vol. 4, pp 1-73. Edited by Atta-ur-Rahman. Bentham Science, Sharjah, United Arab Emirates.

EDUCATION

Biochemistry and Molecular Pathology

RESEARCH INTEREST

Cancer research, Transcription factors, non-coding RNAs

EDITORSHIP

He has published more than 70 papers in reputed journals and has been serving as an editorial board member of repute.

Upcoming Conferences